Provention Bio Inc

Provention Bio — Corporate Update (June 2019)

18 slides from Provention Bio's corporate update, Jun 10, 2019

  1. Slide 1: Conference Call to Discuss NIH-Sponsored "At Risk" Study Results

    Conference Call to Discuss NIH-Sponsored “At Risk” Study Results June 10, 2019

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements including, but not limited to, those relating to the Company’s product development, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of op

  3. Slide 3: Call Participants

    Call Participants —— Speakers ¢ Ashleigh Palmer, Chief Executive Officer & Co-Founder ¢ Eleanor (Leni) Ramos, M.D., Chief Medical Officer and Chief Operating Officer * Kevan Herold, M.D., Professor of Immunobiology and Medicine at Yale University Available for Q&A ¢ Francisco Leon, M.D., Ph.D., Chie

  4. Slide 4: "At Risk" Study Results

    “At Risk” Study Results —/ Landmark study provides first evidence that clinical type 1 diabetes (T1D) can be delayed with early preventive treatment e NlH-sponsored study, conducted by TrialNet, evaluated PRV-031 (teplizumab) in “At Risk” patients e Results show that PRV-031 delayed the clinical ons

  5. Slide 5: T1D: A Serious, Life Changing Autoimmune Disease

    T1D: A Serious, Life Changing Autoimmune Disease... and no new therapies developed since insulin (~100 years) ~40,000 patients New diagnoses each year in US ~1.25 million patients Living with T1D in the US >75% with poorly controlled T1D HbAlc >7.0% Leads to cardiovascular issues, retinopathy, kidne

  6. Slide 6: Provention's PRV-031 Addresses T1D Continuum

    Provention’s PRV-031 Addresses T1D Continuunt | Stage 1 Stage 2 Stage 3 Auto-antibodies Auto-antibodies Auto-antibodies Normoglycemia Dysglycemia Hyperglycemia Pre-symptomatic Symptomatic T1D 100% ALRisk Stud Disease FISK Study Interception 8 (PRV-031) = & PROTECT Study s oO a o = 2 x3) = =] rm 0% i

  7. Slide 7: Anti-CD3 mAB (Teplizumab) For Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus

    Anti-CD3 mAB (Teplizumab) For Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus Study Chair: Kevan Herold MD Yale University

  8. Slide 8: Thank You Sponsors & Supporters

    Thank You Sponsors & Supporters Sponsors NIH) ieee, § NIAID and Kidney Diseases Supporters JDRF ,A Bates’ = HELMSLEY

  9. Slide 9: How We Got Here

    How We Got Here Prevention of Autoimmune Diabetes With Nonactivating Anti-CD3 Monoclonal Antibody KEVAN C. HEROLD, JEFFERY A. BLUESTONE, ANTHONY G. MONTAG, ASHU PARIHAR, AMY WIEGNER, RONALD E. GRESS, AND RAPHAEL HIRSCH pisne Tes “Vou av, tuARCHT RE Proc. Natl. Acad. Sci. USA Vol. 91, pp. 123-127, Ja

  10. Slide 10: Study Design and Timeline

    Study Design and Timeline Study Design 2-arm, multicenter, randomized, double-masked, placebo-controlled clinical trial. Objective To determine whether intervention with teplizumab will prevent or delay the development of T1D in high-risk autoantibody positive non-diabetic relatives of patients with

  11. Slide 11: Statistical Methods

    Statistical Methods ¢ Primary Outcome: ¢ The primary endpoint was a comparison of the time to T1D diagnosis. ¢ The cumulative incidence of diabetes onset over time since randomization within each group was estimated from a Kaplan-Meier estimate of the “diabetes-free” survival function ¢ Tests of sig

  12. Slide 12: Baseline Characteristics

    Baseline Characteristics Teplizumab Placebo N=44 N=32 Age - years (IQR) 14 (12 - 22) 13 (11 - 16) Male 25 (56.8) 17 (63.1) Race: White 44 (100.0) 30 (93.8) African American 0 (0.0) 0 (0.0 Asian/Pacific Islander 0 (0.0) 2 (6.2 Glycated hemoglobin - percent 5.2 (4.9 - 5.4) 5:3:(bL = 54) C-peptide AUC

  13. Slide 13: An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

    The NEW ENGLAND JOURNAL of MEDICINE ORIGINAL ARTICLE An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes Kevan C. Herold, M.D., Brian N. Bundy, Ph.D., S. Alice Long, Ph.D., Jeffrey A. Bluestone, Ph.D., Linda A. DiMeglio, M.D., Matthew J. Dufort, Ph.D., Stephen E. Gitelman, M.D

  14. Slide 14: Time to T1D by Treatment Group

    Time to TLD by Treatment Group Rx Group TiD-Free 1D 24 —— Placebo 9 23 —— Teplizumab 5 19 Proportion T1D-Free 0.14 + Censored 32 23 18 16 5 "1 8 8 6 4 Placebo 0.0" ag 4a 40 *% a a 18 14 10 9 Teplicumab fe) 12 24 36 48 60 On-study (months) T1D was diagnosed in 19 (43%) in teplizumab and 23 (72%) in p

  15. Slide 15: Adverse Events Possibly, Probably, or Definitely Related to Study Drug

    Adverse Events Possibly, Probably, or Definitely Related to Study Drug by treatment group Teplizumab Placebo No.of | No.of | No.of | No.of Adverse Effect Category Events | Subjects | Events | Subjects Blood/Bone Marrow*** 45 33 (75) 2 2 (6.2) Dermatology/Skin™* 17 | 16 (36.4) 1 1.1) Pain 1 5 (114) 5

  16. Slide 16: Summary

    Summary ¢ Asingle two-week treatment with teplizumab delayed the onset of T1D in non-diabetic relatives who were at very high risk for development of clinical T1D. ¢ The delay in the median time to diabetes was 2 years *« 43% of teplizumab treated subjects developed T1D as compared with 72% of those

  17. Slide 17: Significance of the Results

    Significance of the Results * This is the first trial that met its clinical endpoint in delaying the onset of Type 1 diabetes. At the end of the trial, 25/44 (57%) were diabetes free. The longest subject was followed > 7 yrs (88 mos). ¢ The overall incidence of T1D decreases after childhood, and thu

  18. Slide 18: Q&A

Provention Bio — Corporate Update (June 2019) on 6ix